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This multi-centre UK study assesses the impact of predictive testing for breast and ovarian cancer predisposition genes (BRCA1/2) in
the clinical context. In the year following predictive testing, 261 adults (59 male) from nine UK genetics centres participated; 91 gene
mutation carriers and 170 noncarriers. Self-report questionnaires were completed at baseline (pre-genetic testing) and 1, 4 and 12
months following the genetic test result. Men were assessed for general mental health (by general health questionnaire (GHQ)) and
women for general mental health, cancer-related worry, intrusive and avoidant thoughts, perception of risk and risk management
behaviour. Main comparisons were between female carriers and noncarriers on all measures and men and women for general mental
health. Female noncarriers benefited psychologically, with significant reductions in cancer-related worry following testing (Po0.001).
However, younger female carriers (o50 years) showed a rise in cancer-related worry 1 month post-testing (Po0.05). This returned
to pre-testing baseline levels 12 months later, but worry remained significantly higher than noncarriers throughout (Po0.01). There
were no significant differences in GHQ scores between males and females (both carriers and noncarriers) at any time point. Female
carriers engaged in significantly more risk management strategies than noncarriers in the year following testing (e.g. mammograms;
92% carriers vs 30% noncarriers). In the 12 months post-testing, 28% carriers had bilateral risk-reducing mastectomy and 31%
oophorectomy. Oophorectomy was confined to older (mean 41yrs) women who already had children. However, worry about
cancer was not assuaged by surgery following genetic testing, and this requires further investigation. In all, 20% of female carriers
reported insurance problems. The data show persistent worry in younger female gene carriers and confirm changes in risk
management consistent with carrier status. Men were not adversely affected by genetic testing in terms of their general mental health.
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Following the identification of two predisposition genes (BRCA1
and BRCA2) that increase the risk of breast and/or ovarian cancer
(Miki et al, 1994; Wooster et al, 1995), there has been a gradual
introduction of genetic testing into the clinical context. This has
presented a number of challenges for the medical community,
patients and their families. Female carriers of a BRCA1/2 genetic
mutation, not already affected by cancer, have up to 85 and 60%
lifetime risks of developing breast and ovarian cancer, respectively
(Ford et al, 1998). They are at increased risk of early-onset disease
(often pre-menopausal) and bilateral breast cancer (up to 64% by
age 70 years) (Ford et al, 1994). Female BRCA1 carriers who have
had breast cancer before age 60 have an ovarian cancer risk of 44%
by age 70 (Ford et al, 1994). Male carriers have an increased risk of
prostate cancer (6% by age 70) and male and female BRCA1
carriers have an increased risk of bowel cancer (6% lifetime risk)
(Ford et al, 1994). Male BRCA2 carriers have an estimated 6% risk
of breast cancer by age 70 (Easton et al, 1997) and a 10% risk of
prostate cancer (Edwards et al, 2003). There may also be increased
risks of other cancers, although the absolute risks are smaller.
The literature on psychosocial aspects of BRCA1/2 genetic
testing focuses mainly on highly researched cohorts involved in
original linkage studies (Croyle et al, 1997; Lerman et al, 1997;
Smith et al, 1999). There are few large clinical studies and few
include men (Lodder et al, 2001b; Schwartz et al, 2002). Where the
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lpsychological impact of BRCA1/2 testing on men is reported, the
numbers are small and limit interpretation. Most studies assessing
the short-term psychological impact of testing for BRCA1/2
(usually within the month post-genetic test) indicate that
noncarriers experience a reduction in anxiety, whereas carriers
appear to derive few psychological benefits (Lerman et al, 1996;
Croyle et al, 1997; Lodder et al, 2001a; Schwartz et al, 2002). One
meta-analysis (Braithwaite et al, 2004) concluded that there are no
adverse psychosocial sequelae to genetic counselling, but the long-
term impact of genetic testing has not been reviewed due to
insufficient studies. Only one study has described the psycho-
logical impact of testing over the following year, and this was in a
small clinical cohort and cancer worry was not assessed (Meiser
et al, 2002). Data suggest that noncarriers derive psychological
benefits from genetic testing, such as a reduction in worries about
developing cancer. Gene carriers, however, continue to experience
cancer-related distress, which is highest in the month following the
genetic test.
Women with a family history of breast/ovarian cancer tend to
overestimate their risk of developing cancer (Evans et al, 1993;
Watson et al, 1999) and cancer-related distress (Lerman et al,
1995) may interfere with the comprehension of individualised
genetic risk information. If genetic testing is to provide benefits, it
is important to ensure that those offered testing understand risk
information and the advice given, so that informed choices can be
made in relation to risk management.
A primary motivation for many healthy women to proceed with
predictive genetic testing involves reduction of risk, the risk of
developing cancer or dying of cancer (Lodder et al, 1999).
Research evidence is limited regarding management of risk once
carrier status is known. Data have been reported on risk
management intentions in the month following BRCA1/2 testing
(Lerman et al, 1996; Lodder et al, 2001a). Both studies report
similar risk management intentions in terms of risk-reducing
oophorectomy, with about one-third of gene carriers intending to
have their ovaries removed. Intentions to have risk-reducing
mastectomy varied considerably, 17% (two out of 12) (Lerman
et al, 1996) vs 40% (10 out of 25) (Lodder et al, 2001a). However, 1
month post-testing does not provide a long-enough period in
which to assess the risk management implications of genetic
testing in the longer term. It takes time for these services to be put
in place and actual behaviour may differ from intended behaviour.
Individuals identified as BRCA1/2 gene mutation carriers can
potentially reduce the risk associated with breast/ovarian cancer
by electing to undergo risk-reducing surgery, chemoprevention, or
regular surveillance to detect cancer at an early stage when it is
more treatable (Hendrick et al, 1997; Hartmann et al, 2001;
Rebbeck et al, 2002). Studies suggest that surgery (bilateral
mastectomy or oophorectomy) reduces the risk of breast cancer by
90% (Hartmann et al, 2001) and ovarian cancer by up to 95%
(Rebbeck et al, 2002). The effectiveness of chemoprevention (e.g.
Tamoxifen and other selective oestrogen receptor modulators
(SERMS)) for gene carriers is unclear (Eeles and Powles, 2000).
The tendency for a significant proportion of gene carriers
(particularly BRCA1) to have oestrogen-receptor-negative breast
cancer suggests limited efficacy of SERMS in the treatment of
breast cancer in this group (Lakhani et al, 2002). There is limited
evidence on the efficacy of mammography in pre-menopausal
women, although some benefit is likely for those over age 40
(Lalloo et al, 1998; Moller et al, 2002). Lack of efficacy may be due
to screening trials assessing younger age groups (i.e. 40–49 years)
being underpowered rather than limits to the breast X-ray
technique. Surveillance using magnetic resonance imaging (MRI)
may be more sensitive than mammography in this younger age
group, but there is inadequate evidence at present to justify routine
use (Stoutjesdijk et al, 2001). There is also limited evidence on the
rates of breast biopsy following MRI and, due to the limited
specificity of MRI, benign breast disease and cyclical changes may
be treated as suspicious in premenopausal women, leading to
increased invasive diagnostic procedures (Warren et al, 2002).
Trials are underway in the UK to establish the efficacy of ovarian
screening in women at increased risk of ovarian cancer due to
family history over age 35 years (UK Familial Ovarian Cancer
Screening Study) and in the general population over 50 years of
age (UK Trial of Ovarian Cancer Screening).
It is important to evaluate the use of genetic information by the
insurance industry. Patients have declined genetic testing due to
concerns about insurance discrimination (Morrison et al, 1999).
Patients have also experienced problems with insurance discrimi-
nation (Morrison et al, 2000). There is currently a moratorium on
using genetic test results in calculating insurance premiums
(Morrison, 2001). Specifically, the moratorium applies to life
insurance policies up to d500000 and critical illness, long-term
care insurance and income protection up to d300000 for each type
of policy. The use of negative results is encouraged by insurers
where a geneticist can confirm the relevance of the result.
Therefore, we asked study participants to report whether or not
they had experienced any insurance-related problems following
their predictive genetic test.
Due to insufficient evidence to support the introduction of
BRCA1/2 genetic testing into the clinical context, this prospective
study with follow-up to 1 year post-test was undertaken
throughout the UK between 1996 and 2003 (follow-up continuing
to 3 years). The present study includes men and women unaffected
by cancer (i.e. no diagnosed cancer) attending nine centres that
currently undertake the majority of BRCA1/2 testing in clinical
cohorts in the UK. The study aims to document any psychological
morbidity related to genetic testing, ascertain cancer risk
perceptions and examine the ongoing risk management in
BRCA1/2 carriers and noncarriers in the year following genetic
testing. Clarifying whether insurance discrimination has been
experienced as a result of genetic testing is a further aim.
Comparisons will be made between carriers and noncarriers,
men and women. Three key questions are addressed:
What mental health problems exist in men and women and how
are they affected both short and long term by BRCA1/2 genetic
testing?
Do female participants understand their risks of developing
cancer following genetic testing?
How does BRCA1/2 genetic testing impact upon risk manage-
ment for women?
MATERIALS AND METHODS
Participants were unaffected by breast or ovarian cancer at the
time of study entry, from families with an identified BRCA1/2
mutation, and a 50% (25% if an intervening relative had died) risk
of inheriting a BRCA1/2 mutation. Three individuals declined
participation, six declined genetic testing following genetic
counselling and did not receive baseline questionnaires, nine did
not return the study questionnaire, leaving a total of 298 out of 315
(97%) with completed baseline questionnaires (227 females, 71
males).
Procedure
Using a prospective design, adults from nine clinical genetic
centres participated. Trent multi-centre research ethics committee
and all local research ethics committees approved the study. The
consultant geneticist or genetic associate/nurse recruited partici-
pants via clinics between 1996 and 2000. Study entry followed the
genetic counselling consultation prior to the consultation at which
blood was drawn for genetic analysis. Written consent was
obtained.
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testing, was returned directly to the data management centre at the
Institute of Cancer Research, UK. These baseline data are reported
in detail elsewhere (Foster et al, 2002). Follow-up assessment
began once clinicians informed the data centre that participants
had received their genetic test result and questionnaires were
mailed at 1, 4 and 12 months.
Measures
Baseline demographic data included age, level of education,
marital status, number and age of biological children, and social
class. Mutation carrier status was collected from clinics at the end
of the study. Measures selected for validity, reliability and prior
application within genetics research included:
General health questionnaire 28 (GHQ28) (Goldberg and Hillier,
1979): this 28-item measure screens for psychiatric disorder
(cases) in nonpsychiatric populations (clinical case cutoff score
of X10 (binary scoring) was used (Hopwood et al, 1998)). Male
and female participants were assessed at baseline and follow-up.
Cancer worry scale-revised – CWS-R (Watson et al, 1999): this
six-item scale assesses the degree of worry about developing cancer
using a four-point rating from ‘Not at all or rarely’ to ‘Almost all
the time’. A total score on the CWS-R ranges from 6 to 24. A high
score indicates greater worry. No clinical cutoffs are currently
available. The follow-up data yield an alpha coefficient of 0.87.
Female participants were assessed at baseline and follow-up. At the
time the study was designed, knowledge regarding additional risks
to men due to BRCA1/2 mutations was limited; therefore, it was
not deemed appropriate to ask men about their risk of developing
cancer.
Impact of event scale IES (Horowitz et al, 1979): measures the
level of distress in response to a specific traumatic event. A
modified 15-item version (female participants only) assesses
specific thoughts about risk of cancer over the last 7 seven days
(Kash et al, 1992; Watson et al, 1999), with a high score indicating
more frequent intrusive/avoidant thoughts about risk of cancer.
Risk perception At baseline, the perceived risk of developing
breast/ovarian cancer (female participants only) was assessed on a
three-point scale (‘Not very likely’ to ‘Very likely’) or as a stated
percentage or odds ratio. Knowledge of general population risk for
breast/ovarian cancer was assessed. At baseline and 1-month
follow-up, the perceived risk relative to the general population was
rated on a five-point scale (‘Very much lower than average’ to
‘Very much higher’). At 1 and 12 months, women were asked
‘What risk figure have you been given for developing breast/
ovarian cancer?’, with six response options (‘Less than average
woman’, ‘Same as average woman’, ‘50:50 chance’, ‘85% chance’,
‘Other – please specify’, ‘Can’t remember’). Men were asked if they
felt that they were at increased risk of developing cancer (12-
month follow-up only).
Risk management Women reported on the uptake of risk
management options since their genetic test, including mammo-
graphy, Tamoxifen use, bilateral risk-reducing mastectomy
(BRMx), bilateral risk-reducing oophorectomy (BROx), ovarian
ultrasound (Ov US), clinical examination of the breasts by a doctor
(CBE), breast self-examination (BrSE) or any other screening for
cancer. Frequencies of BrSE and breast/ovarian biopsy rates were
recorded.
At all follow-ups, data were collected on number of GP visits
since genetic testing to discuss the result or test-related concerns,
and rates of medication for depression, worry or sleeplessness.
Insurance issues Information was requested on any difficulties
with life or health insurance following their genetic test at 12
months. Participants were not asked if they had declared the test
result to their insurer.
Statistical method
The association between categorical variables is examined using
Fisher’s exact test or the w
2 test, with Yates correction where
appropriate. For ordered categorical variables, the Mann–Whitney
test for trend was used. Age was analysed as a continuous variable
and, in addition, participants were divided into three age groups
(o35, 35–49 and X50 years) chosen to reflect the variations that
might occur in risk management in these age groups especially in
relation to screening by mammography. Women under 35 years
are unlikely to receive a mammogram and women over 50 years
receive regular mammograms as part of the UK National Screening
Programme. Where the o35 and 35–49 year age groups behave in
a similar fashion compared to the 450s, the two younger groups
are reported as one (o50). Scores from the GHQ28, IES and CWS-
R are treated as continuous variables. Normality is tested using the
Kolmogorov–Smirnov statistic and all scores are shown to be non-
normally distributed. Scores are summarised using median and
range. Differences between groups (carriers and noncarriers; men
and women; age groups) were assessed using the Kruskal–Wallis
(KW) test. Changes from baseline were assessed by the signed rank
test. Owing to the relative invariance of the median, the mean
scores are used in the figures. Participants with missing data are
omitted from the respective analyses.
RESULTS
A total of 298 individuals completed baseline questionnaires
(including genetic test decliners) and 285 received a genetic test
result and follow-up questionnaires; 100 (35%) carriers and 185
(65%) noncarriers. In all, 261 participants (92%) returned follow-
up questionnaires overall; 91 (35%) carriers and 170 (65%)
noncarriers. A total of 228 (80%) completed questionnaires were
returned at 1 month (15 were not sent due to administrative error,
1 further questionnaire was not sent due to withdrawn participa-
tion in the study), 242 (85%) at 4 months (four were not sent due
to administrative error) and 235 (82%) at 12 months. The
proportion of carriers and male participants at baseline was the
same for responders at follow-up. There were no differences
between responders and nonresponders in terms of baseline
demographics or psychosocial characteristics. Data for individuals
who declined genetic testing at the time of study entry are reported
elsewhere (Foster et al, 2004).
In all, 23% (N¼59) at follow-up were male, 84% married or
cohabiting, 41% college or university educated, and most men
(73%) and women (67%) were currently employed. The median
age for women was 41 (23–72 years) and 50 (22–86 years) for
men. In all, 45 women and 10 men were o35 years; 107 women
and 18 men were 35–49 years; 48 women and 31 men were X50
years. Among gene carriers, 19 females and six males were o35
years, 42 females and nine males were 35–49, and five females and
10 males were Z50. Most had children (87%) and the median age
of offspring was 19 years (0–50 years). Altogether, 85% described
themselves as Caucasian; 67% of the women and 58% of the men
were noncarriers. Of the 91 carriers, 64 (70%) had BRCA1, 26
(29%) BRCA2 and one (1%) both BRCA1 and BRCA2 genetic
faults.
Participants at each centre (responding at follow-up) were
compared on demographic variables. Three centres (St Mary’s
Hospital Manchester, Royal Marsden Hospital London/Sutton and
Princess Ann Hospital, Southampton) accounted for 82% of
the participants; two smaller centres recruited only women
Psychosocial impact of BRCA1/2 genetic testing
M Watson et al
1789
British Journal of Cancer (2004) 91(10), 1787–1794 & 2004 Cancer Research UK
C
l
i
n
i
c
a
l(Cambridge and Birmingham). There were no differences in
comparisons across the three larger centres, except that the
London/Sutton patients had a marginally higher level of educa-
tional achievement than those from Southampton (P¼0.06).
Participants (n¼47) from the six smaller centres are younger
(Po0.005).
Mental health
There were no baseline differences between carriers and non-
carriers on mental health measures (GHQ P¼0.7, CWS P¼0.9).
GHQ28
There were no significant changes from baseline in GHQ scores in
male carriers (1 month, P¼0.4; 4 months, P¼0.6; 1 year, P¼0.2)
or noncarriers (1 month, P¼0.1; 4 months, P¼0.1; 1 year,
P¼0.7).
Female carriers had significantly higher GHQ total symptom
scores than noncarriers at 1 month (1 (0:26) vs 0 (0:20) P¼0.009)
and 4 (1 (0:20) vs 0 (0:22) P¼0.005) months, but not at 12
months (0 (0:20) vs 0 (0:25) P¼0.4), and had higher GHQ scores
at 1 (0 ( 8:þ18), P¼0.02) and 4 months (0 ( 18: þ19), P¼
0.02) compared to baseline, but this had returned to baseline levels
at 1 year (0 ( 15: þ23), P¼0.6). This increase was only
significant in the 35–49 age group at 1 month (0 ( 4:þ18);
P¼0.02). Low numbers may be the reason for not seeing a
difference in the over 50 group, where there were only five carriers
(Figure 1).
Cancer worry scale-revised (females only)
Carriers reported (Figure 2) significantly higher levels of cancer
worry than noncarriers at all follow-up points (1 month: 13 (6:21)
vs 9 ((:20) Po0.001; 4 months: 11 (6:21) vs 9 (6:16), Po0.001; 1
year: 10 (6:22) vs 9 (6:16), P¼0.003). There was an increase in
worry for carriers at 1 month (þ1(  10: þ13), P¼0.001)
compared to baseline and a decrease at all time points in
noncarriers (1 month:  2(  13: þ6), Po0.001; 4 months:  2
( 12: þ3), Po0.001; 1 year:  2(  14: þ5), Po0.001). At 1
month after genetic test result disclosure, cancer worry in carriers
was higher in the younger age groups (o35: 13 (6:19); 35–49: 13
(7:21)) than in the X50 group (9.5 (7:11)) P¼0.03), but this age
effect was not significant at 1 year. Among noncarriers, the
reduction in cancer worry was greater at each time point in the
younger age group (o50) (1 month:  2(  13: þ6) vs 0(  8:þ3),
P¼0.001; 4 months:  3(  12: þ3) vs  2(  8:þ3), P¼0.001; 1
year:  3(  14: þ4) vs  1(  8:þ5), Po0.001). In all, 39, 24 and
18% of female carriers worried about developing cancer ‘fre-
quently’ or ‘constantly’ at 1, 4 and 12 months, respectively,
compared to just 5, 7 and 5% of noncarriers (Po0.01 at all time
points). Also, 22, 20 and 10% said that their worry was a ‘definite’
or ‘severe’ problem at all time points compared with 3, 2 and 2% of
noncarriers (Po0.01).
Impact of event scale (females only)
There was a significant difference between carriers and noncarriers
at all follow-up points for avoidant (1 month, Po0.001; 4 months,
Po0.001; 1 year, Po0.03) and intrusive thoughts (1 month, Po
0.001; 4 months, Po0.001; 1 year, P¼0.03). Gene carriers showed
no significant increase from baseline in avoidant thoughts, but
there was an increase in intrusive thoughts at 1 month only
compared to baseline (Po0.001).
In total, 20 female carriers, six female noncarriers and three
male carriers sought professional help/advice in the year following
receipt of their genetic test result. Women were asked if they had
taken any medication for depression, worry or sleeplessness. Of
the carriers (noncarriers shown in brackets), nine (3) had taken
medication for depression, seven (10) for worry, four (3) for
sleeplessness and one (1) for unspecified reasons.
Risk perception
At baseline, most women thought that they were at a higher than
average risk of breast (88%) and ovarian cancer (69%). (One
woman who thought her risk of breast cancer was much lower than
average had already had a BRMx.) There was no difference
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Figure 1 Changes in GHQ28 from baseline in the 12 months following
genetic testing.
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Figure 2 Mean cancer worry scores (CWS-R) in the year following
disclosure of BRCA1/2 carrier status (women only).
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Figure 3 Change in risk perception 1 month following the genetic test
result.
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P¼0.4; ovarian cancer P¼0.5; MWTrend). By 1 month follow-up,
risk perception is lower in noncarriers and higher in gene
mutation carriers compared to baseline (see Figure 3). There is
evidence that younger females have increased their perception of
risk (o50 years; P¼0.04; MW) in line with their carrier status.
Scheduled BROx post-testing in the gene carriers has the effect of
lessening the increased risk perception (Po0.05; MW) when
measured 1 month following disclosure of the test result.
At 1 year, 88% of noncarriers rated their risk of breast cancer as
the ‘same as the average woman’. Eight women (7%) said that they
had a less than average risk, two thought they had a slightly higher
than average risk, one woman thought she was at high risk. Among
carriers, most (71%) thought that they had an 85% chance of
developing breast cancer. All other carriers thought they were at
increased risk. No carriers thought that they had an average or less
than average risk. When asked at baseline if they felt at increased
risk of developing other cancers, 25 female carriers said they had
an increased risk of gastro-intestinal cancer, nine lung cancer, five
cervical/endometrial and 10 other cancers of unspecified type.
Nine male carriers said they were at increased risk of gastro-
intestinal cancer, two lung cancer, 13 prostate cancer and three
unspecified cancers.
Risk management
Two women had BRMx (both noncarriers) and 24 BROx (five gene
carriers and 19 noncarriers) prior to genetic testing.
Table 1 illustrates the percentage of women undergoing risk
management procedures in the 12 months following genetic
testing. In all, 20 carriers (31%) had BROx following their genetic
test result, three noncarriers had their ovaries removed following
testing as part of a therapeutic hysterectomy. In all, 42% (20 out of
48) of gene carriers with children (mean 2.5 children; range 1–4)
had BROx following testing compared to those (zero out of 14)
without children (Po0.01). There was marginal evidence that
those having BROx were older; mean age 41 years (range 29–59) vs
37 (range 25–64) (P¼0.06). There were no BRMxs during the year
following predictive testing in noncarriers, but 17 (28%) gene
carriers had this surgery post-genetic testing. All of these women
were o50 years and four were aged o35. The rate of BRMx among
gene carriers varied from centre to centre; 42% (10 out of 24) of
Manchester patients, 36% (four out of 11) of Royal Marsden
Hospital patients, 7% (one out of 14) of Southampton patients and
13% (two out of 15) elsewhere. Six women had both BROx and
BRMx. There was no evidence that having risk-reducing surgery
(N¼30) reduced the levels of cancer worry, avoidant or intrusive
(all P41) thoughts in gene carriers by 12 months follow-up. The
numbers are small and this effect should be interpreted with
caution.
Three women identified as noncarriers subsequently remained
in the Tamoxifen chemoprevention trial (IBIS 1 2003) compared to
two carriers.
Rates of mammography were significantly different (Po0.001)
between carriers (92%) and noncarriers (30%) at 12 months, where
there had previously been no difference at baseline (P41).
Noncarriers who were older (X50) were marginally more likely
to have had a mammogram since their test result than younger
women (41 vs 24%; P¼0.07; Fisher), since they would be included
in the national screening programme and continue to have
increased risk due to age. There were no other age differences.
A similar effect was noted for rates of CBE (90% in carriers vs
89% in noncarriers; P¼0.04) and ovarian US (59% in carriers vs
8% in noncarriers; Po0.001). There were no differences in risk
management options undertaken by BRCA1 and BRCA2 carriers.
These changes in risk management are all in the expected
direction, with a reduction for noncarriers at 12 months follow-up.
There was no evidence that risk management uptake reduced
cancer worry at 1 year (P40.1 for all tests; carriers and
noncarriers). Not surprisingly, carriers who had a breast biopsy
during the year (three patients) had an increase in cancer worry
(P¼0.03).
In all, 87% of women reported practising BrSE at baseline. There
was no difference in baseline frequency between carriers and
noncarriers (P¼0.5). At 1 year, 91% of carriers and 84% of
noncarriers reported practising BrSE (P¼0.02). Since almost all
women reported practising BrSE, it is not possible to demonstrate
a relationship with cancer worry. In total, 29% of women reported
increased frequency of BrSE following testing, with no difference
between carriers and noncarriers (35 vs 28%; P41); 26% of women
reported that they had decreased the frequency of BrSE and this
was more common among noncarriers than carriers (12 vs 31%;
Po0.01). Breast self-examination is recommended on a monthly
basis. Most carriers reported performing BrSE monthly (33%) or
more frequently (39%). However, 18% of carriers performed BrSE
less frequently and 10% never. In comparison, 36% of noncarriers
reported performing BrSE monthly, 21% more frequently, 27% less
frequently and 16% never. At 1 year, 80% of gene carriers and 62%
of noncarriers had read leaflets on breast awareness (P¼0.02).
Most women (82% of carriers and 81% of noncarriers; P¼1.0) had
been shown how to examine their breasts.
Altogether, 52% of female carriers (43% noncarriers) and 44% of
male carriers (44% noncarriers) reported having done something
else to help them stay healthy and/or avoid cancer. They reported
changes in diet (33% female carriers vs 36% NC; 24% male carriers
vs 29% NC) and exercise (17% female carriers vs 19% NC; 20%
male carriers vs 9% NC). Reducing/stopping smoking was reported
by 8% female carriers vs 1% NC (P¼0.04) and 4% male carriers vs
13% NC. Female carriers were more likely than female noncarriers
to report taking vitamins (P¼0.02). There were no differences
between male carriers and noncarriers.
Insurance discrimination (females only assessed)
Five gene carriers reported difficulties in obtaining life insurance
following testing (one was made ‘A-risk’, three were refused
insurance and one could only find one company willing to insure
her), eight (two women had both life and health insurance
problems) gene carriers had difficulties obtaining health insurance
(one was made ‘A risk’, one company will not pay for anything
until the woman gets cancer, one was refused critical illness cover
on her endowment policy, one was refused income protection,
in three cases the company refused to pay for risk-reducing
surgery) and two women had their premiums increased (not
known which insurance)). Thus, in total, 13 female carriers (20%)
experienced some form of insurance problem during the year
following genetic test. In addition, one woman who was a
noncarrier had difficulties with life insurance, where the company
Table 1 Risk management procedures over the 12 months from genetic
testing according to age (X50 or o50 years) and carrier status
(percentage of women)
Carrier
(o50)
Carrier
(X50)
Noncarrier
(o50)
Noncarrier
(X50)
Mammogram 75 100 24 41
CBE 65 100 26 12
Tamoxifen 2 20 1 6
BRMx 28 0 0 0
Ov US 61 40 5 12
BROx 32 40 2 2
Breast biopsy 3 20 4 5
Ovarian biopsy 7 0 0 2
BrSE 96 100 95 88
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have further details regarding why these individuals experienced
problems with their insurance.
DISCUSSION
This study is unique in clarifying what happens during the year
following BRCA1/2 genetic testing now it is becoming routine
clinical practice. Our sample includes a substantial group of men,
most of whom are over 50 years and have children. Male
participants did not report poorer general mental health scores
following genetic testing. For female gene carriers, worry and
mental health problems were highest during the month following
receipt of the genetic test result. These adverse reactions gradually
returned to pre-test baseline levels over the following 12 months.
For noncarriers, there was an immediate and sustained lowering of
cancer-related worry from baseline levels. In this respect,
noncarriers derived most benefit to their mental health, whereas
carriers, after an initial increase, continued to experience the same
level of worry as pre-testing. This reflects the findings from other
studies (Lerman et al, 1997; Reichelt et al, 1999). Among female
carriers, younger (o50 years) women were more likely to report
higher levels of cancer worry in the month following testing, but
they reported similar levels of worry later in the year. A significant
proportion of these women rated their worry as severe or
problematic. It is clear that appropriate services should be put in
place to identify individuals most likely to need extra psychological
support following the test result.
To optimise health benefits, individuals should understand risk
information presented in genetic counselling, so that informed
decisions can be made regarding risk management. It is reassuring
that most noncarriers reported being at a lower risk than at
baseline 1 month following testing. This was maintained a year
after disclosure of carrier status. Younger female carriers were
more likely to report increases in perceived risk of developing
cancer in the year following testing compared to their baseline
responses, but as a group their perceived risk was generally
unchanged from baseline. Women who had risk-reducing surgery
(mastectomy and/or oophorectomy) reported a reduction in their
risk of developing cancer.
Given that one aim of predictive testing for BRCA1/2 is to
reduce mortality by regular surveillance or surgery, it is important
to clarify concerns and support those having difficulty engaging in
appropriate risk management options. In terms of risk
management, this study provides some useful data on the cohort
of carriers and noncarriers, which has not been reported
elsewhere. Carriers were likely to engage in risk management,
noncarriers were less likely to engage in risk management, as
expected. However, although noncarriers do not have a BRCA1/2
mutation that predisposes them to breast/ovarian cancer at a
younger than expected age, they are still at population risk.
Sporadic breast/ovarian cancers are most likely to occur after
the menopause; therefore, it is possibly of concern that a
significant proportion of noncarriers report reducing the
frequency of BrSE following their test result, and this is generally
in older women. It is not clear, however, if this merely represents a
drop in BrSE to that of the general female population. Nonetheless,
this may be a potential area for additional information to
noncarriers as they remain at population risk for breast
cancer and this risk increases with age. In all, 41% of female
noncarriers over 50 years had received a mammogram in the year
following testing. This would appear in keeping with the 3-yearly
interval of the UK national breast-screening programme. Never-
theless, it is important to ensure that women do not interpret a
negative genetic testing as eliminating their cancer risk. It
may be that 12 months is too short a time period to fully assess
the overall impact of testing on participation in screening
programmes or uptake of risk-reducing surgery. A further
assessment at 3 years following testing is currently ongoing and
these data will be reported in due course.
It is striking that a number of women had risk-reducing surgery
(oophorectomy or bilateral mastectomy) prior to genetic testing.
The majority of these were subsequently identified as noncarriers.
Most will have had this surgery prior to the availability of genetic
testing. For the two noncarriers who had BRMx and the 19 who
had BROx, this surgery might have been avoided if genetic testing
had been available to them when surgery was being contemplated.
In this respect, genetic testing will likely save some women
unnecessary surgery and reduce costs to the NHS and the women
themselves. On this basis, risk-reducing surgery should preferably
not be offered to unaffected women until the possibility of having a
genetic test to clarify her status has been fully explored.
There was no evidence to suggest that having risk-reducing
surgery reduced the levels of cancer worry, or avoidant/intrusive
thoughts 1 year following testing. This merits further investigation
as worry levels in gene carriers remained high over the year
following genetic testing. It may be the case that some women had
only just completed their surgery on either their breasts or ovaries
(BRMx or BROx), and had not yet had intended surgery on the
other organ still at risk. It would be helpful to ascertain why there
was a residual high level of cancer-related worry where women had
risk-reducing surgery, as these data would appear to contradict
other available evidence (Hatcher et al, 2001).
Three noncarriers chose to remain in the IBIS (Tamoxifen)
chemoprevention trial in the year following genetic testing, and
could have been discharged from this study on the basis that they
no longer met criteria for inclusion.
Few individuals regretted their decision to have a predictive
genetic test and most were pleased. However, 20% of female gene
carriers experienced some form of insurance discrimination
during the year following genetic testing, which is high, consider-
ing that some will not have applied for insurance in the year
following testing. We do not have more detailed information on
insurance-related problems at this stage, but we are collecting
additional information at 3-year follow-up. Even one case of
discrimination gives rise to worries about the use of genetic
information by the insurance industry. Given that there is
currently a moratorium on using genetic testing results in
calculating insurance premiums (Morrison, 2001), it is of concern
that so many women reported experiencing problems.
Study participants were recruited from nine centres offering
genetic testing for BRCA1/2 between 1996 and 2000. Three centres
recruited most participants as they had an established clinical
service in place at the time the study began. Far fewer individuals
were recruited from other centres; therefore there may be some
differences in participant responses that are a factor of the clinical
service. However, these data provide an important overview of
patient experiences in the period following testing in a group of
centres, providing a significant proportion of genetic testing
during the recruitment period. Nonresponders at follow-up did not
have significantly different worry, mental health or risk perception
scores at baseline, and did not differ significantly in terms of
demographic characteristics. We do not know the carrier status of
nonresponders.
In summary, these data illustrate that while general mental
health and cancer-related worry are reduced in noncarriers in the
year following testing, carriers receive few psychological benefits
from discovering their carrier status – particularly among younger
women. In the future, genetic testing is likely to become more
accessible and more rapid. Pre-test counselling should continue to
be provided. Younger women appear to be the most vulnerable
group. Many carriers in this cohort, especially younger women,
experienced increased levels of distress in the short term following
disclosure of their test result, which then returned to pre-test
levels. In addition to the absence of psychological benefits of
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ltesting in younger female carriers, there is no clear evidence
regarding the medical or psychological benefits of continued
breast/ovarian surveillance in this group; however, this requires
further investigation. It is important that genetic counselling and
support is also available in clinics following disclosure of the test
result in order to address concerns, receive information to
make informed choices and continue to be supported both
medically and psychologically. The development of carrier clinics
may improve access to information and support. Regular updates
of new options via leaflets, information packs, the Internet or
family study days will keep patients up to date. Mental health
liaison services should also be made available for those experien-
cing persistent distress.
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